Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naturally or surgically menopausal~* Moderate or severe symptoms of vaginal atrophy~* 5% or fewer superficial cells in maturation index of vaginal smear~* Vaginal pH greater than 5.0~* Self reported Most Bothersome Symptom of vaginal dryness or vaginal pain associated with sexual activity, with a severity of moderate or severe at randomization~Exclusion Criteria:~* Uterine bleeding of unknown origin, uterine polyps or symptomatic and/or large uterine fibroids~* Current vaginal infection requiring medication~* Clinically significant abnormal gynecological findings other than signs of vaginal atrophy (e.g.~uterine or vaginal prolapse of Grade 2 or higher)~* Previous participation in any other ospemifene study

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ospemifene 60 mg/day and K-Y® lubricant (Type: EXPERIMENTAL): Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
- Placebo and K-Y® lubricant (Type: PLACEBO_COMPARATOR): Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).